1
|
Alcantara M, Houillier C, Garff‐Tavernier M, Souchet L, Roos‐Weil D, Morel V, Uzunov M, Metz C, Nguyen‐Quoc S, Jacque N, Gauthier N, Cann M, Norol F, Willems L, Waultier Rascalou A, Salanoubat C, Fior R, Blonski M, Rubio M, Soussain C, Choquet S. CAR‐T CELL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL): THE EXPERIENCE OF THE FRENCH NETWORK FOR OCULO‐CEREBRAL LYMPHOMAS (LOC). Hematol Oncol 2021. [DOI: 10.1002/hon.74_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
| | - C. Houillier
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | | | - L. Souchet
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | - D. Roos‐Weil
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | - V. Morel
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | - M. Uzunov
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | - C. Metz
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | - S. Nguyen‐Quoc
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | - N. Jacque
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | - N. Gauthier
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | - M. Cann
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | - F. Norol
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | | | | | - C. Salanoubat
- Centre Hospitalier Sud Francilien 91106 Corbeil Essonnes France
| | - R. Fior
- Hôpital Antoine‐Béclère 92140 Clamart France
| | - M. Blonski
- Centre Hospitalier Régional et Universitaire de Nancy 54035 Nancy France
| | - M.‐T. Rubio
- Centre Hospitalier Régional et Universitaire de Nancy 54035 Nancy France
| | | | - S. Choquet
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| |
Collapse
|
2
|
Fodil S, Raffoux E, Dumas PY, Desbrosses Y, Larosa F, Chantepie S, Larcher MV, Mear JB, Peterlin P, Hunault-Berger M, Hospital MA, Morel V, Lucas N, Vidal V, Salanoubat C, Michel J, Mediavilla C, Ojeda-Uribe M, Alexis M, Frayfer J, Carré M, Maillard N, Redjoul R, Banos A, Detrait M, Cluzeau T, Wickenhauser S, Chaoui D, Elassy M, Pigneux A, Dombret H, Récher C, Bertoli S. Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 2021; 62:1756-1760. [PMID: 33596765 DOI: 10.1080/10428194.2021.1881505] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- S Fodil
- Service d'Hématologie adulte, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France
| | - E Raffoux
- Service d'Hématologie adulte, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France
| | - P Y Dumas
- Service d'Hématologie, CHU Bordeaux, F-33000, Bordeaux, France
| | - Y Desbrosses
- Service d'Hématologie, CHRU Jean Minjoz, Besançon, France
| | - F Larosa
- Service d'Hématologie, CHU de Dijon, Dijon, France
| | - S Chantepie
- Service d'Hématologie, Institut d'Hématologie de Basse-Normandie CHU de Caen, Caen, France
| | - M V Larcher
- Service d'Hématologie, Hospices civils de Lyon, CHU de Lyon, Lyon, France
| | - J B Mear
- Service d'Hématologie, CHU de Rennes - Hôpital Pontchaillou, Rennes, France
| | - P Peterlin
- Service d'Hématologie, CHU de Nantes, Nantes, France
| | - M Hunault-Berger
- Service des Maladies du Sang, Centre Hospitalier Universitaire, FHU GOAL, CRCINA, INSERM, Angers, France
| | - M A Hospital
- Service d'Hématologie, Institut Paoli-Calmettes, Marseille, France
| | - V Morel
- Service d'Hématologie, Hôpital Pitié-Salpêtrière AP-HP, Paris, France
| | - N Lucas
- Service d'Hématologie, Institut Gustave Roussy, Villejuif, France
| | - V Vidal
- Service d'Hématologie, Hôpital Avicenne AP-HP, Bobigny, France
| | - C Salanoubat
- Service d'Hématologie, C.H. Sud Francilien, Corbeil-Essonnes, France
| | - J Michel
- Service d'Hématologie, C.H.R. - Hôpital Félix Maréchal, Metz-Thionville, France
| | - C Mediavilla
- Service d'Hématologie, Hôpital Saint-Antoine AP-HP, Paris, France
| | - M Ojeda-Uribe
- Service d'Hématologie, Groupe Hospitalier Régional Mulhouse Sud-Alsace, Mulhouse, France
| | - M Alexis
- Service d'Hématologie, CHR Orléans, Orléans, France
| | - J Frayfer
- Service d'Hématologie, Grand Hôpital de l'Est Francilien - Site de Meaux, Meaux, France
| | - M Carré
- Service d'Hématologie, CHU Grenoble Alpes, La Tronche, France
| | - N Maillard
- Service d'Hématologie, CHU de Poitiers, Poitiers, France
| | - R Redjoul
- Service d'Hématologie, CHU Henri Mondor, AP-HP et UPEC, Créteil, France
| | - A Banos
- Service d'Hématologie, Centre hospitalier de la côte basque, Bayonne, France
| | - M Detrait
- Service d'Hématologie, CHRU de Nancy, Nancy, France
| | - T Cluzeau
- Département d'Hématologie, Université Cote d'Azur, CHU de Nice, Nice, France
| | | | - D Chaoui
- Service d'Hématologie, CH d'Argenteuil, Argenteuil, France
| | - M Elassy
- Service d'Hématologie, CH d'Auxerre, Auxerre, France
| | - A Pigneux
- Service d'Hématologie, CHU Bordeaux, F-33000, Bordeaux, France
| | - H Dombret
- Service d'Hématologie adulte, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France
| | - C Récher
- Service d'Hématologie, CHU de Toulouse, Centre de Recherches en Cancérologie de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse 3 Paul Sabatier, Toulouse, France
| | - S Bertoli
- Service d'Hématologie, CHU de Toulouse, Centre de Recherches en Cancérologie de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse 3 Paul Sabatier, Toulouse, France
| | | |
Collapse
|
3
|
Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia 2015; 30:897-905. [PMID: 26500139 DOI: 10.1038/leu.2015.296] [Citation(s) in RCA: 89] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Revised: 07/28/2015] [Accepted: 08/04/2015] [Indexed: 01/01/2023]
Abstract
After failure of erythropoiesis-stimulating agents (ESAs), lenalidomide (LEN) yields red blood cell (RBC) transfusion independence (TI) in 20-30% of lower-risk non-del5q myelodysplastic syndrome (MDS). Several observations suggest an additive effect of ESA and LEN in this situation. We performed a randomized phase III study in 131 RBC transfusion-dependent (TD, median transfusion requirement six RBC units per 8 weeks) lower-risk ESA-refractory non-del5q MDS. Patients received LEN alone, 10 mg per day, 21 days per 4 weeks (L arm) or LEN (same schedule) + erythropoietin (EPO) beta, 60,000 U per week (LE arm). In an intent-to-treat (ITT) analysis, erythroid response (HI-E, IWG 2006 criteria) after four treatment cycles (primary end point) was 23.1% (95% CI 13.5-35.2) in the L arm and 39.4% (95% CI 27.6-52.2) in the LE arm (P=0.044), while RBC-TI was reached in 13.8 and 24.2% of the patients in the L and LE arms, respectively (P=0.13). Median response duration was 18.1 and 15.1 months in the L and LE arms, respectively (P=0.47). Side effects were moderate and similar in the two arms. Low baseline serum EPO level and a G polymorphism of CRBN gene predicted HI-E. Combining LEN and EPO significantly improves erythroid response over LEN alone in lower-risk non-del5q MDS patients with anemia resistant to ESA.
Collapse
Affiliation(s)
- A Toma
- Department of Hematology, Hopital Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris (APHP) and Paris 12 University, Creteil, France
| | - O Kosmider
- Assistance Publique-Hopitaux de Paris, Hopital Cochin, Laboratory of Hematology and Paris Descartes University, Paris, France
| | - S Chevret
- Biostatistics Team (ECSTRA), UMR1153, Inserm, Hopital Saint Louis, APHP and Paris 7 University, Paris, France
| | - J Delaunay
- Department of Hematology, Centre Hospitalier Universitaire, Nantes, France
| | - A Stamatoullas
- Department of Hematology, Centre Henri Becquerel, Rouen, France
| | - C Rose
- Department of Hematology, Hopital Saint Vincent de Paul, Lomme, France
| | - O Beyne-Rauzy
- Department of Hematology, Centre Hospitalier Universitaire, Purpan, France
| | - A Banos
- Department of Hematology, Centre Hospitalier Universitaire, Strasbourg, France
| | - A Guerci-Bresler
- Department of Hematology, Centre Hospitalier Universitaire, Nancy, France
| | - S Wickenhauser
- Department of Hematology, Centre Hospitalier Universitaire, Nimes, France
| | - D Caillot
- Department of Hematology, Centre Hospitalier Universitaire, Dijon, France
| | - K Laribi
- Department of Hematology, Centre Hospitalier, Le Mans, France
| | - B De Renzis
- Department of Hematology, Centre Hospitalier Universitaire, Clermont Ferrand, France
| | - D Bordessoule
- Department of Hematology, Centre Hospitalier Universitaire, Limoges, France
| | - C Gardin
- Department of Hematology, Hopital Avicenne, APHP, and Paris 13 University Bobigny, Bobigny, France
| | - B Slama
- Department of Hematology, Centre Hospitalier, Avignon, France
| | - L Sanhes
- Department of Hematology, Centre Hospitalier, Perpignan, France
| | - B Gruson
- Department of Hematology, Hopital Universitaire Amiens, Amiens, France
| | - P Cony-Makhoul
- Department of Hematology, Centre Hospitalier Annecy-Genevois, Prigny, France
| | - B Chouffi
- Department of Hematology, Centre Hospitalier, Boulogne sur Mer, France
| | - C Salanoubat
- Department of Hematology, Centre Hospitalier, Corbeil, France
| | - R Benramdane
- Department of Hematology, Centre Hospitalier, Pontoise, France
| | - L Legros
- Department of Hematology, Centre Hospitalier Universitaire, Nice, France
| | - E Wattel
- Department of Hematology, Centre Hospitalier Edouard Herriot, Lyon, France
| | - G Tertian
- Department of Hematology, Hopital Kremlin Bicetre, APHP, Kremlin Bicetre, France
| | - K Bouabdallah
- Department of Hematology, Centre Hospitalier Universitaire, Bordeaux, France
| | - F Guilhot
- Department of Hematology, Centre Hospitalier Jean Bernard, Poitiers, France
| | - A L Taksin
- Department of Hematology, Centre Hospitalier, Versailles, France
| | - S Cheze
- Department of Hematology, Centre Hospitalier Universitaire, Caen, France
| | - K Maloum
- Department of Hematology, Hopital Pitie Salpetriere, APHP and Paris 6 University Paris, Paris, France
| | - S Nimuboma
- Department of Hematology, Centre Hospitalier Universitaire, Rennes, France
| | - C Soussain
- Department of Oncology, Centre Rene Huguenin, Saint Cloud, France
| | - F Isnard
- Department of Hematology, Hopital Saint Antoine, APHP, and Paris 6 University Paris, Paris, France
| | - E Gyan
- Department of Hematology, Centre Hospitalier Universitaire, Tours, France
| | - R Petit
- Departement de Recherche Clinique, Hopital Saint Louis, APHP, Paris, France
| | - J Lejeune
- Biostatistics Team (ECSTRA), UMR1153, Inserm, Hopital Saint Louis, APHP and Paris 7 University, Paris, France
| | - V Sardnal
- Assistance Publique-Hopitaux de Paris, Hopital Cochin, Laboratory of Hematology and Paris Descartes University, Paris, France
| | - A Renneville
- Department of Biology, Centre Hospitalier Universitaire, Lille, France
| | - C Preudhomme
- Department of Biology, Centre Hospitalier Universitaire, Lille, France
| | - M Fontenay
- Assistance Publique-Hopitaux de Paris, Hopital Cochin, Laboratory of Hematology and Paris Descartes University, Paris, France
| | - P Fenaux
- Department of Hematology, Service Hematologie Seniors, Hopital Saint Louis, APHP, and Paris 7 University Paris, Paris, France
| | - F Dreyfus
- Department of Hematology, Hopital Cochin, APHP, and Paris 5 University Paris, Paris, France
| |
Collapse
|
4
|
Campelo MD, Lorenzo J, Itzykson R, Rojas S, Berthon C, Luño E, Beyne-Rauzy O, Pérez-Oteyza J, Vey N, Bargay J, Park S, Cedena T, Bordessoule D, Muñoz J, Gyan E, Such E, Visanica S, Benlloch L, de Botton S, Hernández-Rivas J, Ame S, Stamatoullas A, Delaunay J, Salanoubat C, Isnard F, Guieze R, Sanz G, Cañizo M, Fenaux P. 213 AZACITIDINE (AZA) IN HIGHER RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES (ABN 7): RESULTS OF A RETROSPECTIVE STUDY FROM THE GFM AND GESMD REGISTRIES. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30214-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
5
|
Itzykson R, Thépot S, Beyne-Rauzy O, Ame S, Isnard F, Dreyfus F, Salanoubat C, Taksin AL, Chelgoum Y, Berthon C, Malfuson JV, Legros L, Vey N, Turlure P, Gardin C, Boehrer S, Ades L, Fenaux P. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine? Leuk Res 2011; 36:397-400. [PMID: 22177456 DOI: 10.1016/j.leukres.2011.11.019] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2011] [Revised: 11/10/2011] [Accepted: 11/24/2011] [Indexed: 11/25/2022]
Abstract
We studied a retrospective cohort of 282 higher-risk MDS treated with azacitidine, including 32 patients who concomitantly received an ESA for a median of 5.8 months after azacitidine onset. Forty-four percent of ESA and 29% of no-ESA patients reached HI-E (p=0.07); 48% and 20% achieved transfusion independence (p=0.01). Median OS was 19.6 months in the ESA and 11.9 months in the no-ESA groups (p=0.04). Addition of an ESA significantly improved OS (p=0.03) independently of azacitidine schedule and duration, and of our proposed azacitidine risk score (Blood 2011;117:403-11). Adding an ESA to azacitidine in higher-risk MDS should be studied prospectively.
Collapse
Affiliation(s)
- R Itzykson
- Service d'Hématogie Clinique Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, and Paris 13 University, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Salanoubat C, Delmer A, Marie JP. [Chronic lymphoid B-cell leukemia]. Rev Med Suisse 2006; 2:2498-502. [PMID: 17120720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Affiliation(s)
- C Salanoubat
- Département d'hématologie et d'oncologie médicale, Hôpital Hôtel-Dieu, Assistance publique Hôpitaux de Paris, 75181 Paris cedex 04
| | | | | |
Collapse
|
7
|
Abstract
Extracts of the plant St John's wort, Hyperforin perforatum L., have been used for centuries in traditional medicine, notably for the treatment of depression. One of their main lipophilic components, a natural prenylated phloroglucinol termed hyperforin (HF), has been identified as the major molecule responsible for the antidepressant effects of this plant. Within the last few years, a number of studies have demonstrated that HF displays, in addition, several other biological properties of potential pharmacological interest. They include an antibacterial capacity and inhibitory effects on inflammatory mediators. It is worth noting that HF also promotes apoptosis of various cancer cells from solid tumors and hematological malignancies, including B-cell chronic lymphocytic leukemia. In addition, HF inhibits the capacity of migration and invasion of different tumor cells, as well as exhibiting antiangiogenic effects. Altogether, these properties qualify HF as a lead structure for the development of new therapeutic molecules in the treatment of various diseases, including some malignant tumors.
Collapse
Affiliation(s)
- C Quiney
- UMRS 736 INSERM/Université Paris VI, Centre de Recherches Biomédicales des Cordeliers, Paris Cedex, France
| | | | | | | | | |
Collapse
|
8
|
Quiney C, Billard C, Faussat AM, Salanoubat C, Ensaf A, Naït-Si Y, Fourneron JD, Kolb JP. Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia. Leukemia 2006; 20:491-7. [PMID: 16424868 DOI: 10.1038/sj.leu.2404098] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The effects of the hyperforin (HF), a natural phloroglucinol purified from Hypericum perforatum, were investigated ex vivo on leukemic cells from patients with B-cell chronic lymphocytic leukemia (B-CLL). HF was found to promote apoptosis of B-CLL cells, as shown by time- and dose-dependent stimulation of phosphatidylserine externalization and DNA fragmentation, by disruption of the mitochondrial transmembrane potential, caspase-3 activation and cleavage of the caspase substrate PARP-1. Moreover, HF-induced downregulation of Bcl-2 and Mcl-1, two antiapoptotic proteins that control mitochondrial permeability. HF also downregulated two proteins which are overexpressed by B-CLL patients' cells, the cell cycle inhibitor p27kip1 through caspase-dependent cleavage into a p23 form, and the nitric oxid (NO) synthase of type 2 (inducible NO synthase). This latter was accompanied by reduction in the production of NO known to be antiapoptotic in B-CLL cells. Preventing effects of the general caspase inhibitor z-VAD-fmk indicated that HF-promoted apoptosis of B-CLL cells was mostly caspase dependent. Furthermore, normal B lymphocytes purified from healthy donors appeared less sensitive to HF-induced apoptosis than B-CLL cells. These results indicate that HF may be of interest in the development of new therapies for B-CLL based on the induction of apoptosis and combination with cell cycle-dependent antitumor drugs.
Collapse
Affiliation(s)
- C Quiney
- UMR 736 INSERM/Université Paris VI, Centre de Recherches Biomédicales des Cordeliers, Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
Mantle cell lymphomas are characterized by a male predominance with a range between 55 and 65 years (sex ratio M/F of 6.5). When the sex ratio of patients having mantle cell lymphoma was compared to that of each of the subtypes of non-Hodgkin's lymphomas, it was significantly higher in all cases except Burkitt's and lymphoblastic T-cell lymphomas. These observations suggest a possible relation between the chromosome X and mantle cell lymphomas which has to be explored.
Collapse
Affiliation(s)
- D Decaudin
- Department of Hematology, Institut Curie, Paris, France.
| | | | | |
Collapse
|